Since June 2026, the landscape of obesity treatments has changed in France. Two weight loss injections, semaglutide (Wegovy) and tirzepatide (Mounjaro), are now reimbursed under strict conditions by the Health Insurance. This decision opens up controlled access to molecules that have long been reserved for type 2 diabetes, but it also raises questions about eligibility criteria, medical follow-up, and weight regain after stopping treatment.
Reimbursement conditions in France: limited access for severe obesity
The reimbursement granted since June 15, 2026, does not apply to anyone wishing to lose a few kilos. The criteria are precise: BMI greater than or equal to 40, or BMI greater than or equal to 35 with obesity-related comorbidity (diabetes, hypertension, sleep apnea). An additional condition applies: the patient must have undergone nutritional management for at least six months without achieving a weight loss of at least 5%.
Further reading : Discover the essential trends and news in digital marketing for 2024
The reimbursement rate is set at 65% of the treatment price, with the remainder potentially covered by supplementary health insurance. Outside of these criteria, neither the Health Insurance nor mutual insurance companies cover these molecules. For moderate overweight or grade 1 obesity without comorbidity, the cost remains entirely the responsibility of the patient.
Several healthcare professionals detail weight loss injections for losing weight, reminding that the initial prescription must come from a specialist doctor (endocrinologist, hospital nutritionist). Since June 2025, general practitioners can renew the prescription, but only as a second intention and after specialized advice.
Read also : The Latest Trends and Essential Tips for Preparing Your Next Trip
Semaglutide or tirzepatide: what distinguishes them pharmacologically
Both molecules belong to the family of GLP-1 analogs, an intestinal hormone that regulates blood sugar and appetite. Semaglutide (Wegovy) exclusively targets GLP-1 receptors. Tirzepatide (Mounjaro) acts on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
This dual action of tirzepatide seems to produce a more pronounced weight loss in clinical trials. Tirzepatide is considered more powerful by several doctors, especially for patients with severe obesity and insulin resistance. In contrast, semaglutide has a longer clinical track record and a better-documented side effect profile.
Both treatments share a common mechanism:
- Reduction of appetite by acting on the hunger centers in the brain, which decreases the feeling of hunger between meals
- Slowing down gastric emptying, prolonging satiety after each meal
- Regulation of blood sugar, limiting insulin spikes and associated cravings
The choice between the two molecules depends on the patient’s metabolic profile, history, and tolerance to side effects. This choice is the responsibility of the prescribing specialist, not the patient.
Side effects and at-risk populations: what field reports show
The most common side effects are digestive: nausea, vomiting, diarrhea, constipation. They mainly occur during the first weeks of treatment and tend to decrease with the gradual increase in doses.
In people aged 65 and older, side effects seem to differ from those observed in younger adults. Recent data suggest sometimes poorer digestive tolerance and an increased risk of dehydration in this age group. Close medical monitoring remains the norm for these patients.
Another concerning signal for healthcare professionals is the misuse of these injections by people without obesity. Doctors are worried about a growing demand among patients with simple overweight or even normal weight, motivated by trends circulated on social media. Outside of a strict medical framework, these treatments expose patients to risks without proven benefits.
Weight regain after stopping treatment: a known but underestimated limit
The most delicate question concerns the durability of results. Available data indicate that the majority of patients regain weight after stopping the injections. The mechanism is logical: these molecules act on appetite and metabolism as long as they are present in the body. Once treatment is stopped, hormonal signals return to their previous state.
This reality raises the question of treatment duration. Is it a lifelong treatment to maintain weight loss? Field reports vary on this point. Some specialists consider prolonged treatment for the most severe obesity, while others recommend limited cycles combined with enhanced nutritional and behavioral support.
The current reimbursement framework does not specify a maximum treatment duration. This lack of a time limit could impact the budgets of the Health Insurance if the number of eligible patients increases, which remains likely with the gradual expansion of prescribers.
Regulated prescription and parallel market: two realities that coexist
In France, these injections require a prescription. The initial prescription is reserved for specialists, and renewal by the general practitioner follows a defined protocol. This framework aims to limit inappropriate prescriptions.
In parallel, an online market has developed. Platforms offer quick consultations leading to prescriptions, sometimes without thorough clinical examination. Buying these treatments outside the medical circuit exposes patients to counterfeit risks and deprives them of appropriate follow-up. Health authorities regularly remind that these molecules are not over-the-counter weight loss products.
- The initial prescription must be made by an endocrinologist or a hospital nutritionist
- Renewal by a general practitioner is only possible after an initial specialized assessment
- Any injection purchased without a valid prescription or from an unapproved site presents a real health risk
GLP-1-based injections represent a real therapeutic advance for patients with severe obesity. Their effectiveness on weight loss is documented, and their reimbursement is now effective under strict conditions. Weight regain after stopping and misuse remain the two blind spots of this class of medications, and long-term data are still lacking to determine the optimal treatment duration.